Hospitals and affiliated cardiovascular professionals participating in ACC's NCDR registries can take advantage of the following resources to help meet certain requirements under the federal Quality Payment Program (QPP).
Learn more about the program and check your participation status via the official Centers for Medicare and Medicaid Services (CMS) QPP website.
Don't MIPS Out!
The Merit-Based Incentive Payment System (MIPS) is one way to participate in the QPP and there are currently three MIPS reporting options available: 1) Traditional MIPS; 2) Alternative Payment Model (APM) Performance Pathway; and 3) MIPS Value Pathways (MVPs).
The ACC's Reduce the Risk: PCI Bleed and Professional Data Portfolio App count as Improvement Activities under the Traditional MIPS option. In addition, clinicians affiliated with hospitals participating in ACC's CathPCI Registry or Chest Pain–MI Registry may be eligible to earn MIPS Improvement Activity credit if the facility submits COVID-19 data for patients in these registries. You can claim a Quality Campaign Participation Certificate by taking ACC's MIPS survey. To claim a COVID-19 Participation Certificate you can take ACC's COVID-19 MIPS survey.
Learn more about MIPS reporting options and specific requirements on the CMS website. The 2023 MIPS quick start guide is also available for download.
Note: You can now sign in to submit and review your data for the 2022 performance year until March 31, 2023 at 8 p.m. ET when the submission window closes. More details are available on the CMS QPP website.
The CMS Bundled Payments for Care Improvement (BPCI) Advanced program qualifies as an advanced alternative payment (APM) model under the QPP. BPCI Advanced clinicians who voluntarily participate in this model and meet relevant payment or patient thresholds can also qualify for the Advanced APM bonus and be exempt from MIPS.
Several ACC registry-based quality measures are part of BPCI Advanced, including:
- Defect Free Care for Myocardial Infarction (AMI) - NQF #2377 (PDF)
- Discharge Medications (Angiotensin-Converting Enzyme / Angiotensin Receptor Blocker and Beta Blockers) in Eligible Implantable Cardiac Defibrillator/Cardiac Resynchronization Therapy Defibrillators Implant Patients (NQF #0965)
- Hospital Risk-Standardized Complication Rate following Implantation of Implantable Cardioverter-Defibrillator (ICD) Composite Measure
- In-Person Evaluation Following Implantation of a Cardiovascular Implantable Electronic Device (CIED) (NQF #2461)
- Risk Standardized Bleeding for Patients Undergoing Percutaneous Coronary Intervention (PCI) (NQF #2459)
- Therapy with Aspirin, P2Y12 Inhibitor, and Statin at Discharge Following Percutaneous Coronary Intervention in Eligible Patients (NQF #0964)
Learn more about the program and access the most recent updates and participation requirements on the CMS Innovation Center website. For more information on Model Year 6 (2023) changes and extensions, go here.
*Note: CMS announced in October 2022 that it would extend the BPCI Advanced Model for two years. Initially set to end on Dec. 31, 2023, the program will now conclude on Dec. 31, 2025. CMS plans to announce a Request for Applications (RFA) in early 2023 for Medicare-enrolled providers and suppliers and Medicare Accountable Care Organizations (ACOs) to participate in the Model's two-year extension (2024-2025).
CathPCI Registry Data Release Consent Form
Chest Pain – MI Registry Data Release Consent Form
EP Device Implant Registry Data Release Consent Form
BPCI Advanced Alternative Quality Measures – CathPCI Registry [PPTX]
BPCI Advanced Alternative Quality Measures – Chest Pain – MI Registry [PPTX]
BPCI Advanced Alternative Quality Measures – EP Device Implant Registry [PPTX]
Webinar: Value Based Purchasing Update: Registry Options for CMS BPCI Advanced [Video]